Lipid Formulations with Juniperonic Acid Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioactive fatty acid supplements lack effective compositions and formulations that enhance their therapeutic efficacy for treating various diseases and conditions, with juniperonic acid (5, 11, 14, 17 (all cis) 20:4) not having been previously investigated as a dietary supplement.
Innovation Solution
Development of lipid compositions containing defined ratios of 5,11,14-eicosatrienoic acid combined with other bioactive fatty acids, such as 5, 9, 12-octadecatrienoic acid, 7, 11, 14-eicosatrienoic acid, and 5, 8, 11, 14-eicosatetraenoic acid, formulated for human consumption, either as esterified triglycerides, diglycerides, or phospholipids, and potentially including antioxidants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioactive fatty acids are used as dietary supplements, then therapeutic benefits are provided, but their bioavailability and stability are insufficient
Solution Approach 1:
The patent combines multiple fatty acids (juniperonic acid, pinolenic acid, gamma-linolenic acid, and others) into composite lipid formulations with specific ratio ranges. This composite approach enhances therapeutic efficacy while improving bioavailability through synergistic interactions between different fatty acid components.
Solution Approach 2:
The patent specifies precise parameter ranges for fatty acid ratios (e.g., juniperonic acid at 10-50% w/w, pinolenic acid at 5-30% w/w) to optimize both therapeutic efficacy and bioavailability. By controlling composition parameters within defined ranges, the formulation achieves reliable therapeutic effects while maintaining high bioavailability.
2Reliability
If bioactive fatty acids are used as dietary supplements, then therapeutic benefits are provided, but their stability is insufficient
Solution Approach 1:
The multi-component fatty acid composite formulation enhances stability through synergistic effects. The specific combination of saturated and unsaturated fatty acids creates a stable composition that resists degradation while maintaining therapeutic efficacy over extended periods.
Solution Approach 2:
The patent defines specific composition parameters including ratio ranges of different fatty acids and inclusion of antioxidants at 0.1-5% w/w. These parameter controls ensure compositional stability while preserving therapeutic effects during storage and administration.
3Adaptability or versatility
If juniperonic acid is used as a dietary supplement, then new therapeutic opportunities are created, but there is lack of defined ratio formulations
Solution Approach 1:
The patent establishes specific parameter ranges for juniperonic acid (10-50% w/w) in combination with other fatty acids, creating defined ratio formulations that balance therapeutic versatility with formulation simplicity. These defined ranges provide clear guidance for manufacturing while enabling broad therapeutic applications.
Data Source
AI summary
Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5, 9, 12-octadecatrienoic acid; 7, 11, 14-eicosatrienoic acid; 5, 8, 11, 14-eicosatetraenoic acid; 9, 12-octadecadienoic acid; 9-octadecenoic acid; 14-methylhexadecanoic acid; 11, 14 eicosadienoic acid, 5, 9-octadecadienoic acid; 5, 11-octadecadienoic acid; 9, 12, 15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.